Next Generation, Radically Smaller Aortic Aneurysm Endograft And Delivery System From Cook Medical Submitted For Clinical Trial Approval
Medical News Today
7th November 2008

Cook Medical, the world leader in endovascular repair of aortic disease, has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration for its new Zenith Low Profile Abdominal Aortic Aneurysm (AAA) Endovascular Graft. With IDE approval, Cook will initiate a clinical trial to evaluate the safety and efficacy of the radically smaller endograft delivery system, that will permit treatment of AAA patients with smaller vascular anatomies who otherwise may not have been candidates for minimally invasive endovascular treatment.
7th November 2008

Cook Medical, the world leader in endovascular repair of aortic disease, has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration for its new Zenith Low Profile Abdominal Aortic Aneurysm (AAA) Endovascular Graft. With IDE approval, Cook will initiate a clinical trial to evaluate the safety and efficacy of the radically smaller endograft delivery system, that will permit treatment of AAA patients with smaller vascular anatomies who otherwise may not have been candidates for minimally invasive endovascular treatment.
Latest news:
1st December 2008 -
Researchers Learn That Some 'Good Cholesterol' Isn't Good Enough
1st December 2008 -
New NPS Patient Resource On Infective Endocarditis, Australia
28th November 2008 -
Opportunity to invest in a novel Acoustic Pressure Sensor for medical applications
27th November 2008 -
Medis And TomTec Launch Joint Cardiac Imaging And Analysis Product
27th November 2008 -
International Medical Team Announces Patient Results In Adult Stem Cell Clinical Study For Pulmonary Hypertension
26th November 2008 -
Why Does It Take So Long For A Correct Diagnosis Of Pulmonary Hypertension?
26th November 2008 -
Dramatic JUPITER Findings Fail To Sway Prescribing Behavior, Poll Shows
15th November 2008 -
Statement By Merck & Co., Inc., In Response To The FDA's Update Regarding A Safety Review On Bisphosphonates Including FOSAMAX®
14th November 2008 -
Arsenic May Increase Risks For Cardiovascular Disease At Current Epa-Regulated Drinking Water Standards
14th November 2008 -
High-Normal Phosphate Levels Linked To Early Atherosclerosis
- 15 January 2009



